Metabolic Health

HFE Genetic Testing Workflow: Who to Test and How to Interpret

HFE genotyping follows elevated iron studies or first-degree relatives of known HH—not unselected population screening. Homozygotes, compound hets, and simple hets map to different next steps.

BY ELENA VOSS 4 MIN READ 3 SOURCES

Genetic report printout with iron panel results, no people — Illustration: Health Canon

In short

Order HFE genotyping after elevated iron studies or for first-degree relatives—not as unselected population screening. Interpret C282Y/C282Y, compound hets, and simple hets differently, then map each result to ferritin stage and unloading need.

Genetics without an iron panel is a riddle. An iron panel without genetics in a high-risk family is a missed prevention chance. The workflow is dual on purpose.

This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.

What are the indication rules for HFE testing?

After abnormal transferrin saturation and/or ferritin, perform HFE mutation analysis per AASLD Recommendation 3. Screen first-degree relatives with iron studies and HFE analysis per Recommendation 5. Societies recommend against general population genetic screening because penetrance is incomplete and variable across ancestries.

Consider hemochromatosis evaluation in porphyria cutanea tarda, chondrocalcinosis, hepatocellular carcinoma, type 1 diabetes contexts, abnormal iron studies, and unexplained chronic liver disease—while remembering secondary iron. The CDC stresses family history conversations, especially siblings, and reminds readers that most genotypically affected people never develop complications.

How should common genotypes be interpreted?

Map results into a hierarchy: C282Y/C282Y, compound heterozygote, H63D/H63D (less classic), simple heterozygotes, and wild-type. Adults who are C282Y/C282Y or compound heterozygotes with high ferritin can enter phlebotomy pathways; normal ferritin supports yearly iron studies rather than reflexive induction.

C282Y heterozygotes and H63D heterozygotes are generally not at risk for progressive symptomatic overload. Overcalling simple heterozygosity as having hemochromatosis creates lifelong anxiety and unnecessary treatment. Under-calling compound heterozygotes with high ferritin delays care that could prevent fibrosis.

Genotype-to-action sketch
Result	Typical next step
C282Y/C282Y + high ferritin	Unload / stage liver if high risk
C282Y/C282Y + normal ferritin	Periodic iron studies
Compound het + high ferritin	Phenotype-driven unloading
Simple het	Usually reassure; minor marker noise possible
Wild-type + overload phenotype	Secondary workup ± non-HFE panel

How do partner testing and cascade logistics work?

For offspring risk counseling, testing the other parent of a child of a proband can show obligate heterozygosity and spare unnecessary child testing when appropriate. Adult first-degree relatives remain the cascade core. Direct-to-consumer genetics without iron panel follow-up is an anti-pattern; so is universal newborn HFE screening as default editorial advice without society support.

With genetic testing available, liver biopsy is not routinely required for diagnosis of HFE hereditary hemochromatosis; it remains mainly for fibrosis staging when ferritin and enzymes signal risk. The AASLD guideline remains the primary codified source for these decision rules in U.S. practice discussions.

What interpretation errors cause the most harm?

DTC genetics without labs. Telling simple heterozygotes they have disease. Reassuring on genotype alone when ferritin is already over 1000 with high enzymes. Ignoring compound heterozygotes who do have high ferritin. Stopping at HFE-negative when severe phenotype demands non-HFE panels and imaging.

Codified rule: genotype after or with phenotype markers; interpret genotype class then map to ferritin stage; cascade first-degree relatives systematically; escalate beyond HFE when severe phenotype is HFE-negative; never use genotype alone as a cirrhosis safety certificate when labs already scream staging need for the liver.

Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease.

Sources & citations

Frequently asked

Questions & answers

When should HFE genotyping be ordered?

AASLD recommends HFE mutation analysis after abnormal transferrin saturation and/or ferritin, and screening first-degree relatives with both iron studies and HFE analysis. It is not a lonely public screening tool for unselected healthy people. Case-finding also appears in contexts such as porphyria cutanea tarda, unexplained chronic liver disease, and other high-yield clinical settings while secondary iron causes are considered.

What does C282Y/C282Y mean clinically?

C282Y homozygosity confirms classic genetic hereditary hemochromatosis risk genotype. Adults with high ferritin can often start phlebotomy pathways; those with normal ferritin need periodic iron studies rather than automatic lifelong weekly phlebotomy. Genotype without ferritin staging is incomplete—some homozygotes never develop progressive overload, and others already need liver staging when ferritin exceeds 1000 µg/L with enzyme elevation.

Are compound heterozygotes the same as simple heterozygotes?

No. Compound heterozygotes (for example C282Y/H63D) require phenotype-driven care: elevated ferritin can warrant unloading similar to homozygotes in practice pathways, while normal ferritin supports surveillance. Simple C282Y or H63D heterozygotes are generally not at risk for progressive symptomatic overload, though minor iron marker abnormalities can occur. Do not tell simple heterozygotes they have hemochromatosis disease.

Should children of a proband always be tested immediately?

Not always. AASLD discusses testing the other parent of a child of a known proband: if the other parent is wild-type for risk alleles, the child is an obligate heterozygote and may avoid unnecessary testing. Adult cascade remains the priority. Timing of pediatric testing is individualized with genetics counseling rather than reflexive kits without context.

What if iron studies are high but HFE is negative?

Consider secondary causes of iron overload or hyperferritinemia and escalate to non-HFE genetic evaluation when the hereditary phenotype is strong. Biopsy may help when diagnosis remains unclear. Do not reassure based on genotype alone if ferritin is already above 1000 µg/L with high enzymes—stage the liver regardless of which gene is eventually identified.